Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
AL amyloidosis is caused by a clonal plasma cell dyscrasia and characterized by progressive
deposition of amyloid fibrils derived from monoclonal Ig light chains, leading to multisystem
organ failure and death. The prognosis for AL amyloidosis with conventional treatment remains
poor, Autologous stem cell transplantation (ASCT) for AL amyloidosis produces high
hematologic and organ responses. However, treatment-related mortality remains high and
reported series are subject to selection bias.